Retrospective Study
Copyright ©The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Apr 18, 2017; 9(11): 544-550
Published online Apr 18, 2017. doi: 10.4254/wjh.v9.i11.544
Efficacy and safety of dual therapy with daclatasvir and asunaprevir in elderly patients
Kazuo Tarao, Katsuaki Tanaka, Akito Nozaki, Akira Sato, Toshiya Ishii, Hirokazu Komatsu, Takaaki Ikeda, Tatsuji Komatsu, Shozo Matsushima, Kenji Oshige
Kazuo Tarao, Tarao’s Gastroenterological Clinic, Yokohama 241-0821, Japan
Katsuaki Tanaka, Akito Nozaki, Gastroenterological Center, Medical Center, Yokohama City University, Yokohama 232-0024, Japan
Akira Sato, Toshiya Ishii, Division of Gastroenterology, Department of Internal Medicine, St. Marianna University, Yokohama City Seibu Hospital, Yokohama 241-0811, Japan
Hirokazu Komatsu, Department of Gastroenterology, Yokohama Municipal Citizen’s Hospital, Yokohama 240-8555, Japan
Takaaki Ikeda, Department of Gastroenterology, Yokosuka General Hospital Uwamachi, Yokosuka 238-8567, Japan
Tatsuji Komatsu, Shozo Matsushima, Department of Clinical Research, National Hospital Organization, Yokohama Medical Center, Yokohama 245-8575, Japan
Kenji Oshige, Yokohama National University, Center for Health Service Sciences, Yokohama 240-8501, Japan
Author contributions: Tarao K designed the research; Tanaka K, Nozaki A, Ishii T, Komatsu H, Ikeda T, Komatsu T and Matsushima S followed up the HCV patients in field practice; Oshige K analyzed the data; Tarao K wrote the paper; all the descriptions of the paper were distributed to all authors and confirmed.
Institutional review board statement: The study was approved by institutional review boards in each hospital and conducted in compliance with the Declaration of Helsinki.
Informed consent statement: Written informed consent was obtained from all patients.
Conflict-of-interest statement: Tanaka K has received research funding from Bristol-Myers Squibb and AbbVie; Nozaki A has received research funding from Gilead Sciences; Tarao K, Sato A, Ishii T, Komatsu H, Ikeda T, Komatsu T, Matsushima S and Oshige K declare that have no conflict of interest.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
Correspondence to: Kazuo Tarao, MD, Tarao’s Gastroenterological Clinic, Taiyo-Building, 2-58-6, Futamatagawa, Asahi-ku, Yokohama 241-0821, Japan.
Telephone: +81-45-3606501 Fax: +81-45-3606502
Received: October 18, 2016
Peer-review started: October 23, 2016
First decision: December 20, 2016
Revised: January 19, 2017
Accepted: February 8, 2017
Article in press: February 13, 2017
Published online: April 18, 2017
Core Tip

Core tip: Recently, it was demonstrated that dual oral therapy with daclatasvir and asunaprevir without pegylated-interferon/ribavirin was well tolerated and achieved high sustained virological response rates in Japanese patients with chronic hepatitis C virus genotype Ιb infection, including patients with liver cirrhosis (Child A stage). However, the efficacy and side effects of these drugs was previously studied in non-elderly patients (less than 70 years of age). Those in elderly patients, who are supposed to have higher incidence of hepatocellular carcinoma, have not been studied. We demonstrated that efficacy and side effects in elderly patients were nearly the same as in non-elderly patients.